Summary
Nucleix has developed a highly innovative process for cancer diagnostics. The company plans to introduce Innovative Technique for Lung Cancer Diagnostics via identification of changes in DNA Methylation in Blood Samples. The company has already introduced successfully the Bladder EpiCheck and gained experience in the process of: clinical validation, regulatory approvals and commercialization of bladder cancer diagnostic of cancer via identification of changes in DNA Methylation. Nucleix’s current technology of lung cancer detection in blood samples – Lung EpiCheck - was developed using the same technology and team which has successfully developed Bladder EpiCheck.
Nucleix breakthrough innovations are in the area of cancer detection using a unique combination of a best-in-class biochemical tool, combined with advanced big-data bioinformatics analysis. Lung EpiCheck is a high-potential innovation idea and though having some risk in the process of market adaptation it creates a very high commercial opportunity for Nucleix for growth and a successful mature enterprise
At present, lung cancer is usually detected at late stages, where survival rates are very low – about 15%. The reason for this is that lung cancer patients are mostly asymptomatic in early stages. Detecting lung cancer in early stages significantly improves survival rates to 50% to 80%, thus a good tool for lung cancer detection has huge potential.
The current high clinical results of Lung EpiCheck and the meetings with European potential customers (such as leading medical centers and lab chains) shows that the project proposed methodology and the expected performance is very promising to potential customers and market leaders. These potential customers have also confirmed company’s assumption about pricing that provides proper value for money. Nucleix’s technology is expected to create a huge value proposition to patients, physicians and payers identified as the main stakeholders
Nucleix breakthrough innovations are in the area of cancer detection using a unique combination of a best-in-class biochemical tool, combined with advanced big-data bioinformatics analysis. Lung EpiCheck is a high-potential innovation idea and though having some risk in the process of market adaptation it creates a very high commercial opportunity for Nucleix for growth and a successful mature enterprise
At present, lung cancer is usually detected at late stages, where survival rates are very low – about 15%. The reason for this is that lung cancer patients are mostly asymptomatic in early stages. Detecting lung cancer in early stages significantly improves survival rates to 50% to 80%, thus a good tool for lung cancer detection has huge potential.
The current high clinical results of Lung EpiCheck and the meetings with European potential customers (such as leading medical centers and lab chains) shows that the project proposed methodology and the expected performance is very promising to potential customers and market leaders. These potential customers have also confirmed company’s assumption about pricing that provides proper value for money. Nucleix’s technology is expected to create a huge value proposition to patients, physicians and payers identified as the main stakeholders
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/829218 |
| Start date: | 01-11-2018 |
| End date: | 30-04-2021 |
| Total budget - Public funding: | 3 509 375,00 Euro - 2 456 562,00 Euro |
Cordis data
Original description
Nucleix has developed a highly innovative process for cancer diagnostics. The company plans to introduce Innovative Technique for Lung Cancer Diagnostics via identification of changes in DNA Methylation in Blood Samples. The company has already introduced successfully the Bladder EpiCheck and gained experience in the process of: clinical validation, regulatory approvals and commercialization of bladder cancer diagnostic of cancer via identification of changes in DNA Methylation. Nucleix’s current technology of lung cancer detection in blood samples – Lung EpiCheck - was developed using the same technology and team which has successfully developed Bladder EpiCheck.Nucleix breakthrough innovations are in the area of cancer detection using a unique combination of a best-in-class biochemical tool, combined with advanced big-data bioinformatics analysis. Lung EpiCheck is a high-potential innovation idea and though having some risk in the process of market adaptation it creates a very high commercial opportunity for Nucleix for growth and a successful mature enterprise
At present, lung cancer is usually detected at late stages, where survival rates are very low – about 15%. The reason for this is that lung cancer patients are mostly asymptomatic in early stages. Detecting lung cancer in early stages significantly improves survival rates to 50% to 80%, thus a good tool for lung cancer detection has huge potential.
The current high clinical results of Lung EpiCheck and the meetings with European potential customers (such as leading medical centers and lab chains) shows that the project proposed methodology and the expected performance is very promising to potential customers and market leaders. These potential customers have also confirmed company’s assumption about pricing that provides proper value for money. Nucleix’s technology is expected to create a huge value proposition to patients, physicians and payers identified as the main stakeholders
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
